Pharmaceuticals Acquisitions in Illinois

ESTEVE (Esteve Química / ESTEVE CDMO) has acquired Regis Technologies, a Chicago-based contract development and manufacturing organization (CDMO) specializing in small-molecule APIs and separation products. The acquisition gives ESTEVE a physical U.S. presence, expands its early-stage development and cGMP API manufacturing capabilities, and adds ~70 employees to its US team.

Grünenthal has acquired Chicago-based Valinor Pharma, including global rights to Movantik (naloxegol), in a transaction valued at about $250 million. The deal strengthens Grünenthal's U.S. footprint and adds an established pain-management product to its portfolio after Valinor scaled Movantik sales using Apollo Care's commercial and patient-access solutions.

Formosa Laboratories, Inc., a Taiwan-based API supplier and CDMO, has completed its acquisition of SynChem, Inc., a contract research laboratory in suburban Chicago. SynChem will operate as SynChem-Formosa with Dr. W. Paul Mar remaining as CEO as the combined operations expand Formosa's US CDMO capabilities for small-molecule APIs and ADC-related chemistries.

Funds managed by SK Capital Partners completed the acquisition of Catalent Pharma Solutions' Blow‑Fill‑Seal (BFS) sterile CDMO business and relaunched the business as Woodstock Sterile Solutions. The single‑site Woodstock, Illinois operation will operate independently under new CEO Paul Josephs, supporting global pharmaceutical and biologics customers; Catalent was the seller and debt financing was provided by Cerberus Business Finance.